Almirall, a global pharmaceutical company focused on medical dermatology, today unveiled “The Hive,” a groundbreaking scientific research hub located at its R&D center in Barcelona, Spain. The Hive is designed to promote collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s own scientists, creating a unique innovation ecosystem aimed at driving scientific breakthroughs and enhancing research outcomes.
Almirall, a global leader in medical dermatology, has launched “The Hive,” a cutting-edge scientific research hub located at its R&D center in Barcelona, Spain. This initiative is designed to foster collaboration among biotech companies, start-ups, academia, and Almirall’s own researchers, creating a dynamic innovation ecosystem aimed at advancing scientific breakthroughs and enhancing research success.
Building on the foundation of Almirall’s open innovation center, which began operations in 2023, The Hive expands upon early partnerships with ZeClinics, a Contract Research Organization (CRO) specializing in genetics research using zebrafish as a model, and Centrient Pharmaceuticals, a global leader in sustainable biosynthetic pharmaceutical products. The addition of two new collaborators, ADmit Therapeutics and Microomics, marks a significant step in creating this unique ecosystem. ADmit Therapeutics focuses on the early detection of Alzheimer’s and neurodegenerative diseases using a combination of epigenetic and clinical data, while Microomics specializes in metagenomic analysis via advanced DNA sequencing technologies.
The Hive was officially launched as part of Almirall’s 80th anniversary celebrations, which brought together health authorities, representatives from various associations, and institutions that Almirall closely collaborates with. This event highlighted the company’s long-standing commitment to patients, innovation, and advancing healthcare.
Dr. Karl Ziegelbauer, Almirall’s Chief Scientific Officer, emphasized the power of collaboration, stating, “At Almirall, we bring together scientific experts from different disciplines in a collaborative environment. We believe that collaboration pushes the boundaries of science and drives the development of novel solutions. An open innovation ecosystem like The Hive is the foundation for breakthroughs in scientific discovery and product development, enabling us to address critical unmet needs and deliver meaningful progress in healthcare.”
Almirall’s 80th anniversary also marks a significant milestone for the company, which was founded in 1944 with the mission to provide people access to impactful medicines. Today, the company continues to focus on advancing medical dermatology, backed by a strong scientific heritage and deep partnerships with dermatologists worldwide. With over 50 products across various modalities, Almirall has become a leader in medical dermatology in Europe.
In the past decade, Almirall has invested over 1 billion Euros in R&D for medical dermatology, representing more than 12% of its annual net sales. This continuous investment supports research from discovery through to late-stage clinical testing. Almirall’s commitment to understanding patient needs and translating those insights into innovative treatments has earned it the trust of both healthcare professionals and patients.
Carlos Gallardo, Chairman and CEO of Almirall, reflected on the company’s 80-year journey, stating, “Celebrating 80 years is a testament to Almirall’s enduring commitment to innovation and patient care. Our focus on improving patients’ lives and providing meaningful treatments is driven by our family-owned values, thinking in generations. We will continue to prioritize innovation in medical dermatology and focus on science to deliver healthcare solutions.”
About Almirall
Almirall is a global pharmaceutical company committed to transforming the world of medical dermatology. By collaborating closely with leading scientists, healthcare professionals, and patients, Almirall delivers groundbreaking innovations to address patients’ needs. Headquartered in Barcelona, Almirall was founded in 1944 and is publicly traded on the Spanish Stock Exchange (ALM). In 2023, Almirall reported total revenue of €898.8 million, with 1,900 employees worldwide.
